Skip to Content

Alitretinoin Topical Dosage

Applies to the following strength(s): 0.1%

The information at is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Kaposi's Sarcoma

For use in the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma: Initially, a generous amount of alitretinoin topical gel should be applied to each lesion twice a day.

The application frequency may be gradually increased to 3 or 4 times a day according to individual lesion tolerance. If application site toxicity occurs, the application frequency may be reduced. If irritation is severe, application of the drug may be discontinued for a few days until symptoms subside.

Response of Kaposi's sarcoma lesions may be seen as early as 2 weeks after initiating therapy; however, most patients require longer treatment. Some patients required over 14 weeks to respond to therapy. In clinical trials, alitretinoin topical was applied for up to 96 weeks. The manufacturer recommends continuing therapy as long as the patient is deriving benefit.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available


Alitretinoin topical is not indicated when systemic anti-Kaposi's sarcoma treatment is necessary (e.g., greater than 10 new Kaposi's sarcoma lesions in the previous month, symptomatic lymphedema, symptomatic pulmonary Kaposi's sarcoma, or symptomatic visceral involvement). There are no data on the use of alitretinoin topical with systemic anti-Kaposi's sarcoma treatment.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Data not available

Other Comments

Sufficient gel should be applied to cover the lesion with a generous coating. The gel should be allowed to dry for 3 to 5 minutes before covering with clothing. Occlusive dressings should not be used with alitretinoin topical. Application of this gel to normal skin around the lesions should be avoided since unaffected skin may become irritated. The gel should not be applied on or near mucosal surfaces.

Retinoids have been associated with photosensitivity. Patients should be advised to minimize exposure of treated areas to sunlight or other ultraviolet light (e.g., sunlamps) when using alitretinoin topical.